Zobrazeno 1 - 10
of 16
pro vyhledávání: '"John C. Lue"'
Publikováno v:
Journal of the American Academy of Dermatology. 43:656-663
Background: Tazarotene, a potent acetylenic retinoid for topical use, might be expected to benefit photodamaged skin, including improving the classical signs of fine wrinkles, mottled hyperpigmentation, and roughness. Objective: Our purpose was to de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::702137e7d399779e539eb7efcde717fd
https://doi.org/10.1067/mjd.2000.107938
https://doi.org/10.1067/mjd.2000.107938
Autor:
Gerald G. Krueger, Deborah A. Lew-Kaya, Edward Shmunes, John R. Gibson, David J. Friedman, Brian V. Jegasothy, Gerald D. Weinstein, Joseph L. Jorizzo, Roshantha A.S. Chandraratna, John C. Lue, Madeleine Duvic, John Sefton, Nicholas J. Lowe, Eduardo Tschen
Publikováno v:
Journal of the American Academy of Dermatology. 37:85-92
Topical therapy providing initial improvement and maintenance of effect after treatment of the large majority of patients with limited, mild to moderate psoriasis is not presently available. Previous topical retinoids have generally been either ineff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff06078017efaf7fce5201e14b6838a3
https://doi.org/10.1016/s0190-9622(97)70216-0
https://doi.org/10.1016/s0190-9622(97)70216-0
Publikováno v:
Ophthalmologica. 208:32-36
In a 3-month, double-masked, randomized clinical trial, the ocular hypotensive efficacy and systemic safety of 0.5% levobunolol and 2% carteolol were compared in 59 patients with open-angle glaucoma or ocular hypertension. The overall mean decrease i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da2faf508e6a0d845148d803124ee6ad
https://doi.org/10.1159/000310446
https://doi.org/10.1159/000310446
Autor:
William C. Stewart, Rosanelli Eg, Elaine P. Kelley, Iacono Tl, John C. Lue, Croyle Ta, Alan S. Crandall, Beehler Cc, Ostrov Cs, Macdonald Dk
Publikováno v:
Journal of Glaucoma. 1:237-242
Treatment with noncardioselective beta-adrenoceptor antagonists (e.g., 0.5% timolol or 0.5% levobunolol) is standard practice for lowering elevated intraocular pressure (IOP). However, because there are risks and side effects associated with the use
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::836b452336cc7a9cea7a98bbb9492d16
https://doi.org/10.1097/00061198-199201040-00005
https://doi.org/10.1097/00061198-199201040-00005
Autor:
Thom J. Zimmerman, Cdr Neil Choplin, Jack F. Stoecker, Aron D. Rose, Elaine P. Kelley, John C. Lue, David E. Silverstone, Tom Mundorf
Publikováno v:
American Journal of Ophthalmology. 112:56-60
In a three-month, double-masked, randomized clinical trial, we evaluated the once-daily ocular hypotensive efficacy of 0.25% levobunolol and 0.25% timolol in 80 patients with open-angle glaucoma or ocular hypertension. Thirty-seven of the 39 patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9aeea9fc0d652b1c3be62a9fb0b8b79
https://doi.org/10.1016/s0002-9394(14)76213-0
https://doi.org/10.1016/s0002-9394(14)76213-0
Publikováno v:
Clinical therapeutics. 26(1)
Background: Epinastine hydrochloride is an antihistamine with mast cell-stabilizing and anti-inflammatory activity. Objective: The aim of this study was to assess the efficacy and tolerability of ophthalmic epinastine in patients with seasonal allerg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::304cc10bee38d0829912eb856a33d96e
https://pubmed.ncbi.nlm.nih.gov/14996515
https://pubmed.ncbi.nlm.nih.gov/14996515
Autor:
John Koo, Deborah A. Lew-Kaya, Alexandra I. Vasilopoulos, Nicholas J. Lowe, John C. Lue, John R. Gibson, John Sefton
Publikováno v:
Journal of the American Academy of Dermatology. 43(5 Pt 1)
Background: The addition of oral retinoids to phototherapy may accelerate and enhance antipsoriatic efficacy, but can result in systemic adverse events and additional laboratory monitoring costs. Objective: Our purpose was to determine whether the to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d219433d0299b08e405279ef31de0b6e
https://pubmed.ncbi.nlm.nih.gov/11050587
https://pubmed.ncbi.nlm.nih.gov/11050587
Autor:
John Sefton, Mark Ling, Bernard S. Goffe, John R. Gibson, Debra L. Breneman, Leonard J. Swinyer, Mark Lebwohl, R. Gary Sibbald, James Milbauer, Jay R. Grossman, Gerald D. Weinstein, Stephanie H. Pincus, Deborah A. Lew-Kaya, John C. Lue
Publikováno v:
Journal of the American Academy of Dermatology. 39(4 Pt 1)
Background: Topical corticosteroids are often used in the treatment of psoriasis, but long-term use may be associated with serious adverse events such as tachyphylaxis or atrophy of the skin. Tazarotene, a new topical retinoid, has demonstrated signi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f44bdab6431976746109128f5bfc4662
https://pubmed.ncbi.nlm.nih.gov/9777766
https://pubmed.ncbi.nlm.nih.gov/9777766
Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis
Autor:
David I. Wolf, Mark Lebwohl, Tania J. Phillips, Janine M. Quell, Stanley I. Cullen, Roshantha A.S. Chandraratna, Nicholas J. Lowe, Theodore Rosen, John C. Lue, John R. Gibson, Ernest Ast, John Sefton, Carol L. Kulp-Shorten, Jeffrey P. Callen, Steven Hong
Publikováno v:
Journal of the American Academy of Dermatology. 38(5 Pt 1)
Background: A new class of topical receptor-selective acetylenic retinoids, the first of which is tazarotene, has been developed. Objective: Our purpose was to compare the safety, efficacy, and duration of therapeutic effect of 12 weeks of once-daily
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e945d83c8bc8fd98b3bbdcac2ff99dc
https://pubmed.ncbi.nlm.nih.gov/9591815
https://pubmed.ncbi.nlm.nih.gov/9591815
Autor:
Alan I. Mandell, Sanford I. Rakofsky, Elaine P. Kelley, Theresa L. Iacono, Stuart A Terry, James D. Faulkner, Douglas D. Koch, Ronald L. Gross, John C. Lue
Publikováno v:
Journal of cataract and refractive surgery. 23(7)
To evaluate the prophylactic effect of levobunolol 0.5%, timolol 0.5%, or vehicle in reducing the incidence of postoperative intraocular pressure (IOP) spikes of 5 and 10 mm Hg or more in patients having neodymium:YAG (Nd:YAG) laser posterior capsulo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea66a4985db72de92a4b3178cca65056
https://pubmed.ncbi.nlm.nih.gov/9379380
https://pubmed.ncbi.nlm.nih.gov/9379380